BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14-22. [PMID: 21115577 DOI: 10.1634/theoncologist.2010-s4-14] [Cited by in Crossref: 293] [Cited by in F6Publishing: 148] [Article Influence: 29.3] [Reference Citation Analysis]
Number Citing Articles
1 Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. Oncologist 2020;25:e512-9. [PMID: 32162815 DOI: 10.1634/theoncologist.2019-0501] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
2 Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol 2014;10:721. [PMID: 24646661 DOI: 10.1002/msb.145122] [Cited by in Crossref: 216] [Cited by in F6Publishing: 159] [Article Influence: 30.9] [Reference Citation Analysis]
3 Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol. 2019;11:65-73. [PMID: 30705719 DOI: 10.4254/wjh.v11.i1.65] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Funaki M, Kitabayashi J, Shimakami T, Nagata N, Sakai Y, Takegoshi K, Okada H, Murai K, Shirasaki T, Oyama T, Yamashita T, Ota T, Takuwa Y, Honda M, Kaneko S. Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep 2017;7:16978. [PMID: 29208982 DOI: 10.1038/s41598-017-17285-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
5 Ghodasara S, Pahwa S, Dastmalchian S, Gulani V, Chen Y. Free-Breathing 3D Liver Perfusion Quantification Using a Dual-Input Two-Compartment Model. Sci Rep 2017;7:17502. [PMID: 29235486 DOI: 10.1038/s41598-017-17753-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Shan S, Chen W, Jia JD. Transcriptome Analysis Revealed a Highly Connected Gene Module Associated With Cirrhosis to Hepatocellular Carcinoma Development. Front Genet 2019;10:305. [PMID: 31001331 DOI: 10.3389/fgene.2019.00305] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
8 Yin J, Hou P, Wu Z, Wang T, Nie Y. Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma. Tumour Biol. 2015;36:4501-4507. [PMID: 25618599 DOI: 10.1007/s13277-015-3092-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
9 Song J, Gao L, Yang G, Tang S, Xie H, Wang Y, Wang J, Zhang Y, Jin J, Gou Y, Yang Z, Chen Z, Wu K, Liu J, Fan D. MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One 2014;9:e110074. [PMID: 25313882 DOI: 10.1371/journal.pone.0110074] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
10 Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, Montella M. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013;108:222-8. [PMID: 23169288 DOI: 10.1038/bjc.2012.492] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 10.3] [Reference Citation Analysis]
11 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 31.0] [Reference Citation Analysis]
12 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Thoolen B, Ten Kate FJ, van Diest PJ, Malarkey DE, Elmore SA, Maronpot RR. Comparative histomorphological review of rat and human hepatocellular proliferative lesions. J Toxicol Pathol 2012;25:189-99. [PMID: 22988337 DOI: 10.1293/tox.25.189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
14 Wang J, Jain S, Chen D, Song W, Hu CT, Su YH. Development and Evaluation of Novel Statistical Methods in Urine Biomarker-Based Hepatocellular Carcinoma Screening. Sci Rep 2018;8:3799. [PMID: 29491388 DOI: 10.1038/s41598-018-21922-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
15 Pan Y, Wang B, Yang X, Bai F, Xu Q, Li X, Gao L, Ma C, Liang X. CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition. Sci Rep 2015;5:17006. [PMID: 26593394 DOI: 10.1038/srep17006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
16 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
17 Sun J, Lu H, Wang X, Jin H. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal 2013;2013:924206. [PMID: 23431261 DOI: 10.1155/2013/924206] [Cited by in Crossref: 37] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
18 Yang Q, Guo M, Zhou Y, Hu X, Wang Y, Wu C, Yang M, Pei R, Chen X, Chen J. Phosphatidylserine-Specific Phospholipase A1 is the Critical Bridge for Hepatitis C Virus Assembly. Virol Sin. 2019;34:521-537. [PMID: 31161554 DOI: 10.1007/s12250-019-00123-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol. 2013;19:5439-5445. [PMID: 24023486 DOI: 10.3748/wjg.v19.i33.5439] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
20 Xia H, Ooi LL, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7:e44206. [PMID: 22962603 DOI: 10.1371/journal.pone.0044206] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 12.0] [Reference Citation Analysis]
21 Liang TT, Shao Q, Deng ZC, Wang T, Kang QZ. Systemic Expression Analysis Reveals Prognostic Significance of WIPI3 in Hepatocellular Carcinoma. Front Genet 2020;11:847. [PMID: 32973867 DOI: 10.3389/fgene.2020.00847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Miyauchi Y, Yasuchika K, Fukumitsu K, Ishii T, Ogiso S, Minami T, Kojima H, Yamaoka R, Katayama H, Kawai T, Yoshitoshi-Uebayashi EY, Kita S, Yasuda K, Sasaki N, Uemoto S. A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells. Sci Rep 2017;7:9827. [PMID: 28851916 DOI: 10.1038/s41598-017-09391-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
23 Qin Y, Zhong Y, Ma T, Wu F, Wu H, Yu H, Huang C, Li Z. Alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV. Glycoconj J 2016;33:125-36. [PMID: 26833199 DOI: 10.1007/s10719-015-9645-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
24 Brar G, Greten TF, Graubard BI, McNeel TS, Petrick JL, McGlynn KA, Altekruse SF. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. Hepatol Commun 2020;4:1541-51. [PMID: 33024922 DOI: 10.1002/hep4.1564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
25 Özkan A, Stolley D, Cressman ENK, McMillin M, DeMorrow S, Yankeelov TE, Rylander MN. The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review. Micromachines (Basel) 2020;11:E487. [PMID: 32397454 DOI: 10.3390/mi11050487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
26 Mehra M, Chauhan R. Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma. Biomark Cancer 2017;9:1179299X17737301. [PMID: 29147078 DOI: 10.1177/1179299X17737301] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
27 Quan MF, Xiao LH, Liu ZH, Guo H, Ren KQ, Liu F, Cao JG, Deng XY. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin. World J Gastroenterol. 2013;19:7680-7695. [PMID: 24431896 DOI: 10.3748/wjg.v19.i43.7680] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
28 Hennedige T, Venkatesh SK. Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma. World J Gastroenterol 2016;22:205-20. [PMID: 26755871 DOI: 10.3748/wjg.v22.i1.205] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
29 Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, Salleron J, Henrot P. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One 2017;12:e0176118. [PMID: 28441447 DOI: 10.1371/journal.pone.0176118] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
30 Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol. 2019;11:1-18. [PMID: 30705715 DOI: 10.4254/wjh.v11.i1.1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 31.5] [Reference Citation Analysis]
31 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 153] [Article Influence: 24.1] [Reference Citation Analysis]
32 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
33 Jump DB, Depner CM, Tripathy S, Lytle KA. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. Adv Nutr 2015;6:694-702. [PMID: 26567194 DOI: 10.3945/an.115.009423] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]
34 Umeda S, Kanda M, Sugimoto H, Tanaka H, Hayashi M, Yamada S, Fujii T, Takami H, Niwa Y, Iwata N, Tanaka C, Kobayashi D, Fujiwara M, Kodera Y. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer 2017;17:610. [PMID: 28863781 DOI: 10.1186/s12885-017-3629-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Al-Anazi MR, Matou-Nasri S, Abdo AA, Sanai FM, Khan MQ, Albenmousa A, Al-Ashgar HI, Khalaf NZ, Al-Ahdal MN, Al-Qahtani AA. Variations in DEPDC5 gene and its association with chronic hepatitis C virus infection in Saudi Arabia. BMC Infect Dis 2014;14:632. [PMID: 25551790 DOI: 10.1186/s12879-014-0632-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
36 Assi N, Thomas DC, Leitzmann M, Stepien M, Chajès V, Philip T, Vineis P, Bamia C, Boutron-Ruault MC, Sandanger TM, Molinuevo A, Boshuizen HC, Sundkvist A, Kühn T, Travis RC, Overvad K, Riboli E, Gunter MJ, Scalbert A, Jenab M, Ferrari P, Viallon V. Are Metabolic Signatures Mediating the Relationship between Lifestyle Factors and Hepatocellular Carcinoma Risk? Results from a Nested Case-Control Study in EPIC. Cancer Epidemiol Biomarkers Prev 2018;27:531-40. [PMID: 29563134 DOI: 10.1158/1055-9965.EPI-17-0649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 4.7] [Reference Citation Analysis]
37 Xiao B, Liu C, Liu BT, Zhang X, Liu RR, Zhang XW. TTF1-NPs Induce ERS-Mediated Apoptosis and Inhibit Human Hepatoma Cell Growth In Vitro and In Vivo. Oncol Res. 2016;23:311-320. [PMID: 27131317 DOI: 10.3727/096504016X14567549091341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021;27:3466-82. [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Reference Citation Analysis]
39 Jiang YQ, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH. Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. Front Oncol. 2019;9:113. [PMID: 30863723 DOI: 10.3389/fonc.2019.00113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
40 Saha B, Bala S, Hosseini N, Kodys K, Szabo G. Krüppel-like factor 4 is a transcriptional regulator of M1/M2 macrophage polarization in alcoholic liver disease. J Leukoc Biol 2015;97:963-73. [PMID: 25740962 DOI: 10.1189/jlb.4A1014-485R] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
41 Schonfeld M, Zhao J, Komatz A, Weinman SA, Tikhanovich I. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma. J Biol Chem 2020;295:7126-37. [PMID: 32245889 DOI: 10.1074/jbc.RA120.013401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
42 Farha M, Jairath NK, Lawrence TS, El Naqa I. Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.JCO Clin Cancer Inform. 2020;4:1002-1013. [PMID: 33136432 DOI: 10.1200/CCI.20.00077] [Reference Citation Analysis]
43 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020;1:CD011313. [PMID: 31978267 DOI: 10.1002/14651858.CD011313.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Ambade A, Satishchandran A, Gyongyosi B, Lowe P, Szabo G. Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease. World J Gastroenterol. 2016;22:4091-4108. [PMID: 27122661 DOI: 10.3748/wjg.v22.i16.4091] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
45 Sojoodi M, Wei L, Erstad DJ, Yamada S, Fujii T, Hirschfield H, Kim RS, Lauwers GY, Lanuti M, Hoshida Y, Tanabe KK, Fuchs BC. Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prev Res (Phila) 2020;13:497-508. [PMID: 32253266 DOI: 10.1158/1940-6207.CAPR-19-0383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
46 Zhuang L, Wu Y, Han J, Ling X, Wang L, Zhu C, Fu Y. A network biology approach to discover the molecular biomarker associated with hepatocellular carcinoma. Biomed Res Int 2014;2014:278956. [PMID: 24949431 DOI: 10.1155/2014/278956] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
47 Lyra-González I, Flores-Fong LE, González-García I, Medina-Preciado D, Armendáriz-Borunda J. MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine. World J Hepatol 2015;7:1530-40. [PMID: 26085912 DOI: 10.4254/wjh.v7.i11.1530] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
48 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
49 Coia H, Ma N, He AR, Kallakury B, Berry DL, Permaul E, Makambi KH, Fu Y, Chung FL. Detection of a lipid peroxidation-induced DNA adduct across liver disease stages. Hepatobiliary Surg Nutr 2018;7:85-97. [PMID: 29744335 DOI: 10.21037/hbsn.2017.06.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Gao S, Li A, Liu F, Chen F, Williams M, Zhang C, Kelley Z, Wu CL, Luo R, Xiao H. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell. 2013;24:725-737. [PMID: 24332041 DOI: 10.1016/j.ccr.2013.11.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
51 Romualdo GR, Prata GB, da Silva TC, Fernandes AAH, Moreno FS, Cogliati B, Barbisan LF. Fibrosis-associated hepatocarcinogenesis revisited: Establishing standard medium-term chemically-induced male and female models. PLoS One 2018;13:e0203879. [PMID: 30212575 DOI: 10.1371/journal.pone.0203879] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
52 Yang WS, Va P, Bray F, Gao S, Gao J, Li HL, Xiang YB. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One 2011;6:e27326. [PMID: 22205924 DOI: 10.1371/journal.pone.0027326] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.0] [Reference Citation Analysis]
53 Dumenci OE, U AM, Khan SA, Holmes E, Taylor-Robinson SD. Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction. J Hepatocell Carcinoma 2020;7:1-9. [PMID: 32021853 DOI: 10.2147/JHC.S239039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Link T, Iwakuma T. Roles of p53 in extrinsic factor-induced liver carcinogenesis. Hepatoma Res 2017;3:95-104. [PMID: 30123836 DOI: 10.20517/2394-5079.2017.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
55 Chaminda SR, Suchintha T, Anuk NM, Supun DA, Bhagya GM, Habarakada LCA, Janaka SH. Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology - a prospective study. BMC Gastroenterol 2017;17:142. [PMID: 29207969 DOI: 10.1186/s12876-017-0710-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Lee DY, Yun SM, Song MY, Ji SD, Son JG, Kim EH. Administration of Steamed and Freeze-Dried Mature Silkworm Larval Powder Prevents Hepatic Fibrosis and Hepatocellular Carcinogenesis by Blocking TGF-β/STAT3 Signaling Cascades in Rats. Cells 2020;9:E568. [PMID: 32121064 DOI: 10.3390/cells9030568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Potenza N, Castiello F, Panella M, Colonna G, Ciliberto G, Russo A, Costantini S. Human MiR-544a Modulates SELK Expression in Hepatocarcinoma Cell Lines. PLoS One 2016;11:e0156908. [PMID: 27275761 DOI: 10.1371/journal.pone.0156908] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
58 Saalim M, Resham S, Manzoor S, Ahmad H, Bangash TA, Latif A, Jaleel S. IL-22 in hepatocyte's survival of Pakistani patients with end stage liver disease: an insight into IL 22 mediated hepato-regenerative pathway. Mol Biol Rep 2019;46:1127-38. [PMID: 30603953 DOI: 10.1007/s11033-018-04573-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Guan C, Yang F, He X, Li T, Yang Q, He H, Xu M. Clinical significance of microRNA-155 expression in hepatocellular carcinoma. Oncol Lett 2016;11:1574-80. [PMID: 26893782 DOI: 10.3892/ol.2015.4048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
60 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
61 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
62 Xie R, Xu J, Wen G, Jin H, Liu X, Yang Y, Ji B, Jiang Y, Song P, Dong H, Tuo B. The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J Biol Chem 2014;289:19137-49. [PMID: 24847054 DOI: 10.1074/jbc.M113.540047] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
63 Ali Kamkar MM, Ahmad R, Alsmadi O, Behbehani K. Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. J Diabetes Metab Disord. 2014;13:57. [PMID: 24918094 DOI: 10.1186/2251-6581-13-57] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
64 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
65 Yang Y, Hou J, Lin Z, Zhuo H, Chen D, Zhang X, Chen Y, Sun B. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol. 2014;11:184-196. [PMID: 24488178 DOI: 10.1038/cmi.2013.64] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
66 Sauerbeck AD, Laws JL, Bandaru VV, Popovich PG, Haughey NJ, McTigue DM. Spinal cord injury causes chronic liver pathology in rats. J Neurotrauma 2015;32:159-69. [PMID: 25036371 DOI: 10.1089/neu.2014.3497] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
67 Jiang ZC, Tang XM, Zhao YR, Zheng L. A functional variant at miR-34a binding site in toll-like receptor 4 gene alters susceptibility to hepatocellular carcinoma in a Chinese Han population. Tumour Biol. 2014;35:12345-12352. [PMID: 25179842 DOI: 10.1007/s13277-014-2547-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
68 Zhang C, Yang M, Ericsson AC. Antimicrobial Peptides: Potential Application in Liver Cancer. Front Microbiol. 2019;10:1257. [PMID: 31231341 DOI: 10.3389/fmicb.2019.01257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
69 Agrawal P, Nawadkar R, Ojha H, Kumar J, Sahu A. Complement Evasion Strategies of Viruses: An Overview. Front Microbiol 2017;8:1117. [PMID: 28670306 DOI: 10.3389/fmicb.2017.01117] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 18.0] [Reference Citation Analysis]
70 Zhu J, Lin Z, Wu J, Yin H, Dai J, Feng Z, Marrero J, Lubman DM. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res 2014;13:2986-97. [PMID: 24807840 DOI: 10.1021/pr500128t] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 10.3] [Reference Citation Analysis]
71 Thein HH, Khoo E, Campitelli MA, Zaheen A, Yi Q, De P, Earle CC. Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open 2015;3:E208-16. [PMID: 26389099 DOI: 10.9778/cmajo.20140118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
72 Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH, Lim TKH, Goh GBB, Krishnamoorthy TL, Kumar R, Ng TP, Chong SS, Tan HH, Chung AYF, Ooi LLPJ, Chang JPE, Tan CK, Lee CGL. Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Sci Rep. 2019;9:10464. [PMID: 31320713 DOI: 10.1038/s41598-019-46872-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 18.0] [Reference Citation Analysis]
73 Paganoni R, Lechel A, Vujic Spasic M. Iron at the Interface of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4097. [PMID: 33921027 DOI: 10.3390/ijms22084097] [Reference Citation Analysis]
74 Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017;16:499-507. [PMID: 28118080 DOI: 10.1080/15384101.2017.1282586] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
75 Uccello M, Malaguarnera G, Corriere T, Biondi A, Basile F, Malaguarnera M. Risk of hepatocellular carcinoma in workers exposed to chemicals. Hepat Mon. 2012;12:e5943. [PMID: 23162599 DOI: 10.5812/hepatmon.5943] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
76 Zhou L, Du Y, Kong L, Zhang X, Chen Q. Identification of molecular target genes and key pathways in hepatocellular carcinoma by bioinformatics analysis. Onco Targets Ther 2018;11:1861-9. [PMID: 29670361 DOI: 10.2147/OTT.S156737] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
77 Zhao J, O'Neil M, Schonfeld M, Komatz A, Weinman SA, Tikhanovich I. Hepatocellular Protein Arginine Methyltransferase 1 Suppresses Alcohol-Induced Hepatocellular Carcinoma Formation by Inhibition of Inducible Nitric Oxide Synthase. Hepatol Commun 2020;4:790-808. [PMID: 32490317 DOI: 10.1002/hep4.1488] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
78 Wright JH, Johnson MM, Shimizu-Albergine M, Bauer RL, Hayes BJ, Surapisitchat J, Hudkins KL, Riehle KJ, Johnson SC, Yeh MM, Bammler TK, Beyer RP, Gilbertson DG, Alpers CE, Fausto N, Campbell JS. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer. 2014;134:778-788. [PMID: 23929039 DOI: 10.1002/ijc.28421] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
79 Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, Wu CF, Lin CL, Liu CJ, Liaw YF, Lin SM, Chen PJ, Lee SD, Yu MW. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One. 2014;9:e95870. [PMID: 25427199 DOI: 10.1371/journal.pone.0095870] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
80 Testino G, Borro P. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol. 2013;5:521-527. [PMID: 24179611 DOI: 10.4254/wjh.v5.i10.521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
81 Zhao J, O'Neil M, Vittal A, Weinman SA, Tikhanovich I. PRMT1-Dependent Macrophage IL-6 Production Is Required for Alcohol-Induced HCC Progression. Gene Expr 2019;19:137-50. [PMID: 30236171 DOI: 10.3727/105221618X15372014086197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
82 Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 2016;6:21340. [PMID: 26888602 DOI: 10.1038/srep21340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 9.2] [Reference Citation Analysis]
83 Lytle KA, Depner CM, Wong CP, Jump DB. Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway. J Lipid Res 2015;56:1936-46. [PMID: 26315048 DOI: 10.1194/jlr.M061275] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
84 Chandrashekar DS, Golonka RM, Yeoh BS, Gonzalez DJ, Heikenwälder M, Gerwirtz AT, Varambally S, Vijay-Kumar M. Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. PLoS One 2020;15:e0234726. [PMID: 32559205 DOI: 10.1371/journal.pone.0234726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Huang CH, Kuo CJ, Liang SS, Chi SW, Hsi E, Chen CC, Lee KT, Chiou SH. Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma. BBA Clin 2015;3:205-13. [PMID: 26675302 DOI: 10.1016/j.bbacli.2015.02.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
86 Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590-600. [PMID: 25173447 DOI: 10.1007/s00535-014-0993-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
87 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
88 Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 2019;4:130116. [PMID: 31391334 DOI: 10.1172/jci.insight.130116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
89 Najafi Z, Sharifi M, Javadi G. Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma. Cancer Gene Ther 2015;22:530-5. [PMID: 26427512 DOI: 10.1038/cgt.2015.51] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
90 Debaize L, Troadec MB. The master regulator FUBP1: its emerging role in normal cell function and malignant development. Cell Mol Life Sci 2019;76:259-81. [PMID: 30343319 DOI: 10.1007/s00018-018-2933-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
91 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
92 Yoo J, Hann HW, Coben R, Conn M, DiMarino AJ. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases. 2018;6:E27. [PMID: 29677098 DOI: 10.3390/diseases6020027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
93 Tschida BR, Temiz NA, Kuka TP, Lee LA, Riordan JD, Tierrablanca CA, Hullsiek R, Wagner S, Hudson WA, Linden MA, Amin K, Beckmann PJ, Heuer RA, Sarver AL, Yang JD, Roberts LR, Nadeau JH, Dupuy AJ, Keng VW, Largaespada DA. Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. Cancer Res 2017;77:6576-88. [PMID: 28993411 DOI: 10.1158/0008-5472.CAN-17-2281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
94 Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X, Calvisi DF. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Front Oncol 2019;9:1412. [PMID: 31921669 DOI: 10.3389/fonc.2019.01412] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
95 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
96 Mustufa MA, Ozen C, Hashmi IA, Aslam A, Baig JA, Yildiz G, Muhammad S, Solangi IB, Ul Hasan Naqvi N, Ozturk M, Ali FI. Synthesis and bio-molecular study of (+)-N-Acetyl-α-amino acid dehydroabietylamine derivative for the selective therapy of hepatocellular carcinoma. BMC Cancer 2016;16:883. [PMID: 27842576 DOI: 10.1186/s12885-016-2942-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
97 Liu B, Zhang J, Huang C, Liu H. Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One 2012;7:e43147. [PMID: 22912812 DOI: 10.1371/journal.pone.0043147] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
98 Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3:732-736. [PMID: 27275318 DOI: 10.3889/oamjms.2015.111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 9.7] [Reference Citation Analysis]
99 Al-Harbi SA, Abdulrahman AO, Zamzami MA, Khan MI. Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review. Front Nutr 2021;8:647582. [PMID: 34164422 DOI: 10.3389/fnut.2021.647582] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Shiragannavar VD, Gowda NGS, Kumar DP, Mirshahi F, Santhekadur PK. Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC. Front Oncol 2020;10:628506. [PMID: 33585254 DOI: 10.3389/fonc.2020.628506] [Reference Citation Analysis]
101 Yahya SMM, Fathy SA, El-Khayat ZA, El-Toukhy SE, Hamed AR, Hegazy MGA, Nabih HK. Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma. Indian J Clin Biochem 2018;33:21-30. [PMID: 29371766 DOI: 10.1007/s12291-017-0651-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
102 Kim BR, Oh J, Yu KS, Ryu HG. Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation. Br J Clin Pharmacol 2020;86:923-32. [PMID: 31840271 DOI: 10.1111/bcp.14200] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Subramanian R, Singh SA, Gupta S, Majhi SK, Malhotra R. Perioperative anesthetic management of a combined right atrial thrombectomy with living donor liver transplantation. J Anaesthesiol Clin Pharmacol 2019;35:396-9. [PMID: 31543592 DOI: 10.4103/joacp.JOACP_180_18] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Wang R, Hu X, Liu X, Bai L, Gu J, Li Q. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis. PLoS One 2021;16:e0249881. [PMID: 33861762 DOI: 10.1371/journal.pone.0249881] [Reference Citation Analysis]
105 Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342:223-230. [PMID: 22306342 DOI: 10.1016/j.canlet.2012.01.038] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 12.1] [Reference Citation Analysis]
106 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 151] [Article Influence: 44.0] [Reference Citation Analysis]
107 Hodeib H, ELshora O, Selim A, Sabry NM, El-Ashry HM. Serum Midkine and Osteopontin Levels as Diagnostic Biomarkers of Hepatocellular Carcinoma. Electron Physician 2017;9:3492-8. [PMID: 28243398 DOI: 10.19082/3492] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
108 Li QY, Yang K, Liu FG, Sun XG, Chen L, Xiu H, Liu XS. Long noncoding RNA CASC2c inhibited cell proliferation in hepatocellular carcinoma by inactivated ERK1/2 and Wnt/β-catenin signaling pathway. Clin Transl Oncol 2020;22:302-10. [PMID: 31625123 DOI: 10.1007/s12094-019-02223-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
109 Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology 2021;73:2278-92. [PMID: 32931023 DOI: 10.1002/hep.31555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
110 Cynis H, Kehlen A, Haegele M, Hoffmann T, Heiser U, Fujii M, Shibazaki Y, Yoneyama H, Schilling S, Demuth HU. Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol 2013;94:217-25. [PMID: 23560443 DOI: 10.1111/iep.12020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
111 Zheng Y, Liu Y, Zhao S, Zheng Z, Shen C, An L, Yuan Y. Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma. Cancer Manag Res 2018;10:6079-96. [PMID: 30538557 DOI: 10.2147/CMAR.S181396] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
112 Polireddy K, Chavan H, Abdulkarim BA, Krishnamurthy P. Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol 2011;5:410-25. [PMID: 21849266 DOI: 10.1016/j.molonc.2011.07.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
113 Hsueh TP, Tsai TH. Preclinical Pharmacokinetics of Scoparone, Geniposide and Rhein in an Herbal Medicine Using a Validated LC-MS/MS Method. Molecules 2018;23:E2716. [PMID: 30360359 DOI: 10.3390/molecules23102716] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
114 Lin BQ, Zhang WB, Zhao J, Zhou XH, Li YJ, Deng J, Zhao Q, Fu G, Xie CM, Xu YK, Feng GK. An Optimized Integrin α6-Targeted Magnetic Resonance Probe for Molecular Imaging of Hepatocellular Carcinoma in Mice. J Hepatocell Carcinoma 2021;8:645-56. [PMID: 34235103 DOI: 10.2147/JHC.S312921] [Reference Citation Analysis]
115 VoPham T, Brooks MM, Yuan JM, Talbott EO, Ruddell D, Hart JE, Chang CC, Weissfeld JL. Pesticide exposure and hepatocellular carcinoma risk: A case-control study using a geographic information system (GIS) to link SEER-Medicare and California pesticide data. Environ Res 2015;143:68-82. [PMID: 26451881 DOI: 10.1016/j.envres.2015.09.027] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
116 Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90. [PMID: 21953299 DOI: 10.1002/hep.24703] [Cited by in Crossref: 185] [Cited by in F6Publishing: 172] [Article Influence: 18.5] [Reference Citation Analysis]
117 Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther 2018;181:108-25. [PMID: 28723414 DOI: 10.1016/j.pharmthera.2017.07.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 12.5] [Reference Citation Analysis]
118 Padmapriya R, Gayathri L, Ronsard L, Akbarsha MA, Raveendran R. In vitro Anti-Proliferative Effect of Tephrosia purpurea on Human Hepatocellular Carcinoma Cells. Pharmacogn Mag 2017;13:S16-21. [PMID: 28479720 DOI: 10.4103/0973-1296.203981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
119 Lee YS, Seo YS, Kim JH, Lee J, Kim HR, Yoo YJ, Kim TS, Kang SH, Suh SJ, Joo MK, Jung YK, Lee BJ, Yim HJ, Yeon JE, Kim JS, Park JJ, Um SH, Bak YT, Byun KS. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. Gut Liver. 2018;12:94-101. [PMID: 28873509 DOI: 10.5009/gnl17040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
120 Zhao J, Adams A, Roberts B, O'Neil M, Vittal A, Schmitt T, Kumer S, Cox J, Li Z, Weinman SA, Tikhanovich I. Protein arginine methyl transferase 1- and Jumonji C domain-containing protein 6-dependent arginine methylation regulate hepatocyte nuclear factor 4 alpha expression and hepatocyte proliferation in mice. Hepatology 2018;67:1109-26. [PMID: 29023917 DOI: 10.1002/hep.29587] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
121 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
122 Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep 2021;3:100215. [PMID: 33392490 DOI: 10.1016/j.jhepr.2020.100215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
123 Espíndola KMM, Ferreira RG, Narvaez LEM, Silva Rosario ACR, da Silva AHM, Silva AGB, Vieira APO, Monteiro MC. Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma. Front Oncol 2019;9:541. [PMID: 31293975 DOI: 10.3389/fonc.2019.00541] [Cited by in Crossref: 71] [Cited by in F6Publishing: 44] [Article Influence: 35.5] [Reference Citation Analysis]
124 Liu L. Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy. Infect Agent Cancer 2020;15:8. [PMID: 32042307 DOI: 10.1186/s13027-020-0277-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
125 Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer. 2016;8:37-55. [PMID: 27398029 DOI: 10.4137/bic.s34413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
126 Ni F, Gui Z, Guo Q, Hu Z, Wang X, Chen D, Wang S. Downregulation of miR-362-5p inhibits proliferation, migration and invasion of human breast cancer MCF7 cells. Oncol Lett 2016;11:1155-60. [PMID: 26893711 DOI: 10.3892/ol.2015.3993] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
127 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 47] [Article Influence: 18.5] [Reference Citation Analysis]
128 Son YS, Ullah HMA, Elfadl AK, Chung MJ, Ghim SG, Kim YD, Lee EJ, Kang KK, Jeong KS. Preventive Effects of Vitamin C on Diethylnitrosamine-induced Hepatotoxicity in Smp30 Knockout Mice. In Vivo 2018;32:93-9. [PMID: 29275304 DOI: 10.21873/invivo.11209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
129 Chidambaranathan-Reghupaty S, Mendoza R, Fisher PB, Sarkar D. The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma. Hepatoma Res 2018;4:32. [PMID: 32258418 DOI: 10.20517/2394-5079.2018.34] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
130 Goodus MT, Sauerbeck AD, Popovich PG, Bruno RS, McTigue DM. Dietary Green Tea Extract Prior to Spinal Cord Injury Prevents Hepatic Iron Overload but Does Not Improve Chronic Hepatic and Spinal Cord Pathology in Rats. J Neurotrauma 2018;35:2872-82. [PMID: 30084733 DOI: 10.1089/neu.2018.5771] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
131 Hu B, Sun M, Liu J, Hong G, Lin Q. MicroRNA-204 suppressed proliferation and motility capacity of human hepatocellular carcinoma via directly targeting zinc finger E-box binding homeobox 2. Oncol Lett 2017;13:3823-30. [PMID: 28521482 DOI: 10.3892/ol.2017.5907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
132 Romero-Zerbo SY, García-Fernández M, Espinosa-Jiménez V, Pozo-Morales M, Escamilla-Sánchez A, Sánchez-Salido L, Lara E, Cobo-Vuilleumier N, Rafacho A, Olveira G, Rojo-Martínez G, Gauthier BR, González-Mariscal I, Bermúdez-Silva FJ. The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:103. [PMID: 32210914 DOI: 10.3389/fendo.2020.00103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
133 Lou Z, Gong YQ, Zhou X, Hu GH. Low expression of miR-199 in hepatocellular carcinoma contributes to tumor cell hyper-proliferation by negatively suppressing XBP1. Oncol Lett 2018;16:6531-9. [PMID: 30405792 DOI: 10.3892/ol.2018.9476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
134 Lee JH, Suh JH, Choi SY, Kang HJ, Lee HH, Ye BJ, Lee GR, Jung SW, Kim CJ, Lee-Kwon W, Park J, Myung K, Park NH, Kwon HM. Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis. Gut 2019;68:347-58. [PMID: 29420225 DOI: 10.1136/gutjnl-2017-315348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
135 Yadav S, Kashaninejad N, Nguyen NT. RhoA and Rac1 in Liver Cancer Cells: Induction of Overexpression Using Mechanical Stimulation. Micromachines (Basel) 2020;11:E729. [PMID: 32731493 DOI: 10.3390/mi11080729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
136 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
137 Bale G, Steffie AU, Ravi Kanth VV, Rao PN, Sharma M, Sasikala M, Reddy DN. Regional differences in genetic susceptibility to non-alcoholic liver disease in two distinct Indian ethnicities. World J Hepatol 2017;9:1101-7. [PMID: 28989566 DOI: 10.4254/wjh.v9.i26.1101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
138 Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: a review and a point of view. World J Gastroenterol. 2014;20:15943-15954. [PMID: 25473148 DOI: 10.3748/wjg.v20.i43.15943] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
139 Zhang Q, Zhang Y, Sun S, Wang K, Qian J, Cui Z, Tao T, Zhou J. ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway. Cell Death Dis 2021;12:15. [PMID: 33414412 DOI: 10.1038/s41419-020-03291-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Anderton B, Camarda R, Balakrishnan S, Balakrishnan A, Kohnz RA, Lim L, Evason KJ, Momcilovic O, Kruttwig K, Huang Q, Xu G, Nomura DK, Goga A. MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. EMBO Rep 2017;18:569-85. [PMID: 28219903 DOI: 10.15252/embr.201643068] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
141 Rutledge SM, Zheng H, Li DK, Chung RT. No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatoma Res 2019;5:31. [PMID: 31453368 DOI: 10.20517/2394-5079.2019.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
142 Chu YJ, Yang HI, Wu HC, Liu J, Wang LY, Lu SN, Lee MH, Jen CL, You SL, Santella RM, Chen CJ. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int J Cancer. 2017;141:711-720. [PMID: 28509392 DOI: 10.1002/ijc.30782] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 13.8] [Reference Citation Analysis]
143 Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLoS One 2013;8:e83627. [PMID: 24391798 DOI: 10.1371/journal.pone.0083627] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
144 Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int 2017;11:45-53. [PMID: 27271356 DOI: 10.1007/s12072-016-9743-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
145 Kalasekar SM, Kotiyal S, Conley C, Phan C, Young A, Evason KJ. Heterogeneous beta-catenin activation is sufficient to cause hepatocellular carcinoma in zebrafish. Biol Open 2019;8:bio047829. [PMID: 31575545 DOI: 10.1242/bio.047829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
146 Fang CC, Wu CF, Liao YJ, Huang SF, Chen M, Chen YA. AAV serotype 8-mediated liver specific GNMT expression delays progression of hepatocellular carcinoma and prevents carbon tetrachloride-induced liver damage. Sci Rep 2018;8:13802. [PMID: 30217986 DOI: 10.1038/s41598-018-30800-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
147 Niture S, Gyamfi MA, Lin M, Chimeh U, Dong X, Zheng W, Moore J, Kumar D. TNFAIP8 regulates autophagy, cell steatosis, and promotes hepatocellular carcinoma cell proliferation. Cell Death Dis. 2020;11:178. [PMID: 32152268 DOI: 10.1038/s41419-020-2369-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
148 Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications. 2013;27:293-300. [PMID: 23312215 DOI: 10.1016/j.jdiacomp.2012.10.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]